Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells

The emergence of multidrug resistance (MDR) is among the crucial obstacles to breast cancer therapy success. The transcription factor nuclear factor (NF)-kappa B is correlated to the pathogenesis of breast cancer and resistance to therapy. NF-kappa B augments the expression of MDR1 gene, which encodes for the membrane transporter P-glycoprotein (P-gp) in cancer cells. Since NF-kappa B activity is considered to be relatively high in particular when it comes to breast cancer, in the present work, we proposed that the inhibition of NF-kappa B activity can augment and enhance the sensitivity of breast cancer cells to chemotherapy such as doxorubicin (DOX) by virtue of MDR modulation. Our results demonstrated that the DOX-resistant MCF-7 and MDA-MB-231 clones exhibit higher NF-kappa B (p65) activity, which is linked to the upregulated expression of ABCB1 and ABCC1 transporter proteins. Combined treatment with NF-kB inhibitors (pentoxifylline and bortezomib) sensitized the resistant breast cancer cells to DOX. Such synergy was compromised by forced overexpression of p65. The DOX/NF-kappa B inhibitor combinations hampered NF-kappa B (p65) activation and downregulated MDR efflux transporters' level. Breast cancer cell migration was sharply suppressed in cells co-treated with DOX/NF-kappa B inhibitors. The same treatments successfully enhanced DOX-mediated induction of apoptosis, which is reflected by the elevated ratio of annexin-V/PI positively stained cells, along with the activation of other apoptotic markers. In conclusion, the data generated from this study provide insights for future translational investigations introducing the use of the clinically approved NF-kappa B inhibitors as an adjuvant in the treatment protocols of resistant breast cancer to overcome the multidrug resistance and enhance the therapeutic outcomes.

Automated summary

The inhibition of NF-kappa B activity can enhance the sensitivity of breast cancer cells to chemotherapy, particularly doxorubicin, by modulating multidrug resistance. Combined treatment with NF-kappa B inhibitors can sensitize resistant breast cancer cells to doxorubicin, by suppressing NF-kappa B activation and downregulating MDR efflux transporters.